William Faquin

William Faquin


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2023 in Science
Verified
Journal Article
Closed access
RBRuben Bill
Ruben Bill
PWPratyaksha Wirapati
Pratyaksha Wirapati
MMMarius Messemaker
Marius Messemaker
WRWhijae Roh
Whijae Roh
BZBeatrice Zitti
Beatrice Zitti
MPMikael J. Pittet
Mikael J. Pittet
Tumor microenvironments (TMEs) influence cancer progression but are complex and often differ between patients. Considering that microenvironment variations may reveal rules governing intratumoral cellular programs and disease outcome, we focused on tumor-to-tumor variation to examine 52 head and neck squamous cell carcinomas. We found that macrophage polarity—defined by CXCL9 and SPP1 (CS) expression but not by conventional M1 and M2 markers—had a noticeably strong prognostic association. CS macrophage polarity also identified a highly coordinated network of either pro- or antitumor variables, which involved each tumor-associated cell type and was spatially organized. We extended these findings to other cancer indications. Overall, these results suggest that, despite their complexity, TMEs coordinate coherent responses that control human cancers and for which CS macrophage polarity is a relevant yet simple variable.

12 October 2015 in Cancer Cytopathology
Verified
Journal Article
Open access
PDF file
WFWilliam Faquin
William Faquin
LWLawrence Q. Wong
Lawrence Q. Wong
AAAmir H. Afrogheh
Amir H. Afrogheh
SASyed Z. Ali
Syed Z. Ali
JBJustin A. Bishop
Justin A. Bishop
ZBZubair W. Baloch
Zubair W. Baloch
BACKGROUND: Recent discussions have focused on redefining noninvasive follicular variant of papillary thyroid carcinoma (NI‐FVPTC) as a neoplasm rather than a carcinoma. This study assesses the potential impact of such a reclassification on the implied risk of malignancy (ROM) for the diagnostic categories of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC).METHODS: The study consisted of consecutive fine‐needle aspiration biopsy (FNAB) cases collected between January 1, 2013 and June 30, 2014 from 5 academic institutions. Demographic information, cytology diagnoses, and surgical pathology follow‐up were recorded. The ROM was calculated with and without NI‐FVPTC and was presented as a range: all cases (ie, overall risk of malignancy [OROM]) versus those with surgical follow‐up only.RESULTS: The FNAB cohort consisted of 6943 thyroid nodules representing 5179 women and 1409 men with an average age of 54 years (range, 9‐94 years). The combined average ROM and OROM for the diagnostic categories of TBSRTC were as follows: nondiagnostic, 4.4% to 25.3%; benign, 0.9% to 9.3%; atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS), 12.1% to 31.2%; follicular neoplasm (FN), 21.8% to 33.2%; suspicious for malignancy (SM), 62.1% to 82.6%; and malignant, 75.9% to 99.1%. The impact of reclassifying NI‐FVPTC on the ROM and OROM was most pronounced and statistically significant in the 3 indeterminate categories: the AUS/FLUS category had a decrease of 5.2% to 13.6%, the FN category had a decrease of 9.9% to 15.1%, and the SM category had a decrease of 17.6% to 23.4% (P < .05), whereas the benign and malignant categories had decreases of 0.3% to 3.5% and 2.5% to 3.3%, respectfully. The trend of the effect on the ROM and OROM was similar for all 5 institutions.CONCLUSIONS: The results from this multi‐institutional cohort indicate that the reclassification of NI‐FVPTC will have a significant impact on the ROM for the 3 indeterminate categories of TBSRTC. Cancer Cytopathol 2016;124:181–187. © 2015 American Cancer Society.

18 May 2020 in Cancer Cytopathology
Verified
Journal Article
Closed access
PDF file
MNMasato Nakaguro
Masato Nakaguro
YTYuichiro Tada
Yuichiro Tada
WFWilliam Faquin
William Faquin
PSPeter M. Sadow
Peter M. Sadow
LWLori J. Wirth
Lori J. Wirth
Toshitaka NagaoToshitaka Nagao
Toshitaka Nagao

29 November 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GSGiulia Siravegna
Giulia Siravegna
COConnor J. O'Boyle
Connor J. O'Boyle
SVShohreh Varmeh
Shohreh Varmeh
NQNatalia Queenan
Natalia Queenan
AMAlexa Michel
Alexa Michel
DFDaniel Faden
Daniel Faden
Purpose: HPV-associated head and neck squamous cell carcinoma (HPV+HNSCC) is the most common HPV-associated malignancy in the United States and continues to increase in incidence. Current diagnostic approaches for HPV+HNSCC rely on tissue biopsy followed by histomorphologic assessment and detection of HPV indirectly by p16 IHC. Such approaches are invasive and have variable sensitivity. Experimental Design: We conducted a prospective observational study in 140 subjects (70 cases and 70 controls) to test the hypothesis that a noninvasive diagnostic approach for HPV+HNSCC would have improved diagnostic accuracy, lower cost, and shorter diagnostic interval compared with standard approaches. Blood was collected, processed for circulating tumor HPV DNA (ctHPVDNA), and analyzed with custom ddPCR assays for HPV genotypes 16, 18, 33, 35, and 45. Diagnostic performance, cost, and diagnostic interval were calculated for standard clinical workup and compared with a noninvasive approach using ctHPVDNA combined with cross-sectional imaging and physical examination findings. Results: Sensitivity and specificity of ctHPVDNA for detecting HPV+HNSCC were 98.4% and 98.6%, respectively. Sensitivity and specificity of a composite noninvasive diagnostic using ctHPVDNA and imaging/physical examination were 95.1% and 98.6%, respectively. Diagnostic accuracy of this noninvasive approach was significantly higher than standard of care (Youden index 0.937 vs. 0.707, P = 0.0006). Costs of noninvasive diagnostic were 36% to 38% less than standard clinical workup and the median diagnostic interval was 26 days less. Conclusions: A noninvasive diagnostic approach for HPV+HNSCC demonstrated improved accuracy, reduced cost, and a shorter time to diagnosis compared with standard clinical workup and could be a viable alternative in the future.

21 October 2016 in Acta Cytologica
Verified
Journal Article
Open access
PDF file
MPMarc Pusztaszeri
Marc Pusztaszeri
EREsther Diana Rossi
Esther Diana Rossi
MAManon Auger
Manon Auger
ZBZubair Baloch
Zubair Baloch
JBJustin Bishop
Justin Bishop
WFWilliam Faquin
William Faquin
The Bethesda System for Reporting Thyroid Cytology (TBSRTC) was proposed in 2007 at the National Cancer Institute Thyroid Fine Needle Aspiration State of the Art and Science Conference held in Bethesda, Maryland. The aim was to address the inconsistent and sometimes confusing reporting terminologies used for thyroid FNA throughout the world. The TBSRTC consists of 6 diagnostic categories, each associated with an implied risk of malignancy that translates directly into a clinical management algorithm. Since the publication of the TBSRTC cytology Atlas in January 2010, considerable experience has been gained regarding its application in cytology practice, clinical impact, and limitations. In conjunction with the International Academy of Cytology (IAC), an international panel composed of sixteen cytopathologists and an endocrinologist with special interest in thyroid cytology, including several co-authors of the 2010 TBSRTC Atlas, was created to: (1) analyze the current worldwide impact of TBSRTC, (2) report on the current state of TBSRTC based upon a review of the published literature, and (3) provide possible recommendations for a future update of TBSRTC. Herein, we summarize the panel's deliberations and key recommendations that our panel hopes will be useful during the preparation of the second edition of TBSRTC.

12 July 2011 in Cancer Cytopathology
Verified
Journal Article
Closed access
PDF file
MBMassimo Bongiovanni
Massimo Bongiovanni
JKJeffrey F. Krane
Jeffrey F. Krane
ECEdmund S. Cibas
Edmund S. Cibas
WFWilliam Faquin
William Faquin